Clarus Iv-d, L.p. - Net Worth and Insider Trading

Clarus Iv-d, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Clarus Iv-d, L.p. owns 2 companies in total, including Galera Therapeutics Inc (GRTX) , and Talaris Therapeutics Inc (TALS) .

Click here to see the complete history of Clarus Iv-d, L.p.’s form 4 insider trades.

Insider Ownership Summary of Clarus Iv-d, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
GRTX	Galera Therapeutics Inc	2019-11-06	10 percent owner
TALS	Talaris Therapeutics Inc	2021-05-06	10 percent owner

Clarus Iv-d, L.p. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Clarus Iv-d, L.p. Ownership Network

Ownership Network List of Clarus Iv-d, L.p.

No Data

Ownership Network Relation of Clarus Iv-d, L.p.

Clarus Iv-d, L.p. Owned Company Details

What does Galera Therapeutics Inc do?

Who are the key executives at Galera Therapeutics Inc?

Clarus Iv-d, L.p. is the 10 percent owner of Galera Therapeutics Inc. Other key executives at Galera Therapeutics Inc include director & President and CEO Mel Sorensen , Chief Commercial Officer Mark Bachleda , and Chief Financial Officer Chris Degnan .

Galera Therapeutics Inc (GRTX) Insider Trades Summary

Over the past 18 months, Clarus Iv-d, L.p. made no insider transaction in Galera Therapeutics Inc (GRTX). Other recent insider transactions involving Galera Therapeutics Inc (GRTX) include a net purchase of 3,712,809 shares made by , and a net sale of 67,015 shares made by Mel Sorensen .

In summary, during the past 3 months, insiders sold 67,015 shares of Galera Therapeutics Inc (GRTX) in total and bought 0 shares, with a net sale of 67,015 shares. During the past 18 months, 67,015 shares of Galera Therapeutics Inc (GRTX) were sold and 3,712,809 shares were bought by its insiders, resulting in a net purchase of 3,645,794 shares.

Galera Therapeutics Inc (GRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Galera Therapeutics Inc Insider Transactions

No Available Data

Clarus Iv-d, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Clarus Iv-d, L.p.. You might contact Clarus Iv-d, L.p. via mailing address: 101 Main Street, Suite 1210, Cambridge Ma 02142.

Discussions on Clarus Iv-d, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.